 |
Welcome to CytImmune! :: CytImmune Sciences, Inc.
CytImmune is a clinical stage biopharmaceutical based in Rockville, MD. The Company is developing a pipeline of multifunctional, next-generation therapeutics, binding known anti-cancer agents – whose toxicities currently prevent or severely limit clinical use – to its patented colloidal gold tumor-targeting nanotechnology. This approach creates safe therapies for a broad spectrum of cancers, significantly reducing toxicity (and side effects), increasing efficacy and improving quality of life. The goal is to build from this common core technology a family of therapeutics with faster development timelines, efficient regulatory approvals, new commercialization value, and greater patient benefits. Clinical Trial Link: A Phase I Trial of TNF-Bound Colloidal Gold (CYT-6091) byIntravenous Administration in Subjects With Advanced Solid OrganMalignancies Latest News:Maryland Tech Council Names Awards FinalistsCytImmune To Present At ASCOScience Stops for No Ho
Cytimmune.com ~
Site Info
Whois
Trace Route
RBL Check
|
|
|
|